ELP-004

• Description :

  ELP-004 is a TRPC channel inhibitor and inhibtis TRPC channel-mediated Ca2+ entry. ELP-004 is an osteoclast inhibitor and inhibits osteoclast differentiation. ELP-004 inhibits basal Ca2+ and related NFATc1 translocation in inflammatory osteoclastogenesis. ELP-004 reduces bone erosion in a mouse model of rheumatoid arthritis[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  TRP Channel

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Field of Research :

  Inflammation/Immunology

• Concentration :

  10mM

• Purity :

  99.89

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  CCC(N(C1=CC(Cl)=C(C=C1)Cl)C)=O

• Molecular Formula :

  C10H11Cl2NO

• Molecular Weight :

  232.11

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ray S, et al. Targeting TRPC channels for control of arthritis-induced bone erosion. Sci Adv. 2025 Jan 17;11 (3) :eabm9843.|[2]McCall JL, et al. Preclinical evaluation of ELP-004 in mice. Pharmacol Res Perspect. 2024 Aug;12 (4) :e1230.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [15533-81-0]